IL-1 inhibitor in ascites fluids from ovarian cancer patients
Matsuzaki, N.; Samejima, Y.; Azuma, C.; Negoro, T.; Saji, F.; Tanizawa, O.
Nihon Sanka Fujinka Gakkai Zasshi 39(12): 2197-2198
1987
ISSN/ISBN: 0300-9165 PMID: 3501453 Document Number: 289931
Document emailed within 1 workday
Related Documents
Sadłecki, P.ł; Walentowicz-Sadłecka, M.łg.; Szymański, W.ła.; Grabiec, M. 2011: Comparison of VEGF, IL-8 and beta-FGF concentrations in the serum and ascites of patients with ovarian cancer Ginekologia Polska 82(7): 498-502Krasznai, Zárd.Tibor.; Friedländer, E.; Nagy, Aás.; Szabó, Gábor.; Vereb, Görgy.; Goda, K.; Hernádi, Zán. 2005: Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer Anticancer Research 25(2a): 1187-1192
Kunze, M.; Büttner, H.H.; Strache, R.R.; Voss, P.; Briese, V.; Schrodt, U. 1988: CEA determination in aspired fluid of cystic ovarian tumors and ovarian cysts and in ascites and serum samples of patients with ovarian tumors Zentralblatt für Gynakologie 110(16): 1006-1012
Strache, R.R.; Göcze, P.M.; Szábo, D.G.; Büttner, H.H.; Briese, V.; Kunze, M.; Csaba, I.F.; Röpcke, G. 1989: Placental protein 12 (PP 12) in cyst and peritoneal fluids and serum samples of patients with ovarian cysts and cystic ovarian tumors Zentralblatt für Gynakologie 111(11): 749-754
Luesley, D.M.; Williams, D.R.; Ward, K.; Redman, C.R.; Lawton, F.G. 1990: Prospective comparative cytologic study of direct peritoneal smears and lavage fluids in patients with epithelial ovarian cancer and benign gynecologic disease Acta Cytologica 34(4): 539-544
Kikuchi, Y.; Kizawa, I.; Oomori, K.; Miyauchi, M.; Kita, T.; Sugita, M.; Tenjin, Y.; Kato, K. 1987: Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation Cancer Research 47(2): 592-596
Epenetos, A.A.; Hooker, G.; Krausz, T.; Snook, D.; Bodmer, W.F.; Taylor-Papadimitriou, J. 1986: Antibody-guided irradiation of malignant ascites in ovarian cancer: a new therapeutic method possessing specificity against cancer cells Obstetrics and Gynecology 68(3 Suppl): 71s-74s
Kaneko, T.; Kato, Y. 1979: Care of a patient with severe ascites caused by ovarian cancer Nursing Technique 25(11): 55-62
Ivanov, S.; Batashki, I. 2008: Five years survival in patients with endometrioid ovarian cancer versus patients with serous ovarian cancer Akusherstvo i Ginekologiia 47(5): 9-11
Park, C.M.; Kim, S.Y. 2014: Rupture of an endometrioma with extremely high serum CA-125 level (> 10,000 IU/ml) and ascites resembling ovarian cancer European Journal of Gynaecological Oncology 35(4): 469-472
Kawai, S.; Nishida, Y.; Nakada, M.; Tachikawa, M.; Miyagoshi, E. 1985: Standards of nursing of patients with ovarian and uterine cancer--through the nursing actions toward patients with cervical and ovarian cancer scheduled for total hysterectomy Nursing Technique 31(8): 1017-1024
Suzuki, M.; Sekiguchi, I.; Tamada, T.; Sakurabayashi, I.; Kawai, T. 1985: Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors Rinsho Byori. Japanese Journal of Clinical Pathology 33(2): 173-177
Villert, A.B.; Kolomiets, L.A.; Kondakova, I.V.; Spirina, L.V.; Yunusova, N.V. 2016: Proteins of insuline-like growth factor system in tumor and ascites in ovarian cancer: the relation with neoajuvant chemotherapy effectiveness Voprosy Onkologii 62(6): 788-793
Harłozińska, A.; Bar, J.K.; Gawlikowski, W.; Richter, R.; Cisło, M. 1991: CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms Annales Chirurgiae et Gynaecologiae 80(4): 368-375
Fukuyama, A.; Yokoyama, Y.; Wada, J.; Hashimoto, T.; Oda, T.; Sato, S.; Mizunuma, H. 2009: Two cases of ovarian cancer at an early stage incidentally detected using transvaginal ultrasonography in screening: importance of interval for ovarian cancer screening and selection of population with a high risk of ovarian cancer European Journal of Gynaecological Oncology 30(2): 208-210
Yu, Z.; Zhang, Z.; Li, S.; Gao, J. 2011: Effect of a Chloride Channel Inhibitor, 5-nitro-2-(3-phenylpropylamino)-benzoate, on Ovarian Cancer Cell Migration Clinical Laboratory 57(7-8): 543-550
Hartge, P.; Hayes, R.; Reding, D.; Sherman, M.E.; Prorok, P.; Schiffman, M.; Buys, S. 2000: Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial American Journal of Obstetrics and Gynecology 183(5): 1232-1237
Zhang, J.; Kan, Y.; Tian, Y.; Wang, Z.; Zhang, J. 2013: Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance and proliferation of the ovarian cancer C13* cells Indian Journal of Medical Research 137(3): 527-532
Della Porta, P.; Soeltl, R.; Krell, H.W.; Collins, K.; O'Donoghue, M.; Schmitt, M.; Krüger, A. 1999: Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo Anticancer Research 19(5b): 3809-3816
Penault-Llorca, F.; Levrel, O.; Clémenson, A.; Kwiatkowski, F.; Pomel, C.; Fouilhoux, G.; De Latour, M.; Curé, H.; Déchelotte, P.; Fonck, Y.; Dauplat, J. 2000: Assessment of different histoprognosis grading systems for primary ovarian cancer: 100 patients given the same treatment for primary ovarian adenocarcinoma Journal de Gynecologie Obstetrique et Biologie de la Reproduction 29(6): 548-554